Cargando…

Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs

BACKGROUND: Pimobendan, diuretics, and an angiotensin-converting enzyme inhibitor (ACEi) are widely used for the management of chronic valvular heart disease in dogs; however, the effects of that combination on heart rate variability (HRV) are unknown. The purpose of this study was to assess the HRV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirintr, Prapawadee, Saengklub, Nakkawee, Boonpala, Pakit, Hamlin, Robert L., Kijtawornrat, Anusak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568857/ https://www.ncbi.nlm.nih.gov/pubmed/37821927 http://dx.doi.org/10.1186/s12917-023-03770-6

Ejemplares similares

Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration
por: KIJTAWORNRAT, Anusak, et al.
Publicado: (2017)

Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration
por: PIRINTR, Prapawadee, et al.
Publicado: (2017)

Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
por: Saengklub, Nakkawee, et al.
Publicado: (2021)

Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs
por: Pichayapaiboon, Poonavit, et al.
Publicado: (2021)

Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
por: Boonpala, Pakit, et al.
Publicado: (2023)

Acute effect of ivabradine on heart rate and myocardial oxygen consumption in dogs with asymptomatic mitral valve degeneration
por: Pirintr, Prapawadee, et al.
Publicado: (2018)

Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation
por: Tantisuwat, Lalida, et al.
Publicado: (2023)

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs
por: Saengklub, Nakkawee, et al.
Publicado: (2022)

An increasing electromechanical window is a predictive marker of ventricular fibrillation in anesthetized rabbit with ischemic heart
por: Limprasutr, Vudhiporn, et al.
Publicado: (2017)

Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation
por: Saengklub, Nakkawee, et al.
Publicado: (2017)

Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs
por: SAENGKLUB, Nakkawee, et al.
Publicado: (2015)

Short-term effects of oral dronedarone administration on cardiac function, blood pressure and electrocardiogram in conscious telemetry dogs
por: SAENGKLUB, Nakkawee, et al.
Publicado: (2016)

Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease
por: McManamey, Anna K., et al.
Publicado: (2023)

Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease
por: Sarcinella, Fabio, et al.
Publicado: (2019)

Letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Atkins, Clarke, et al.
Publicado: (2021)

Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial
por: Wess, Gerhard, et al.
Publicado: (2020)

Myxomatous degeneration of the mitral valve
por: Neto, Felippe Lazar, et al.
Publicado: (2018)

Letter regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Oyama, Mark A., et al.
Publicado: (2021)

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial
por: Boswood, A., et al.
Publicado: (2016)

Response to letter to editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Wess, Gerhard, et al.
Publicado: (2021)

Response to letter to the editor regarding “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial”
por: Wess, Gerhard, et al.
Publicado: (2021)

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
por: Boswood, A., et al.
Publicado: (2017)

Distinct Mitral Valve Proteomic Profiles in Rheumatic Heart Disease and Myxomatous Degeneration
por: Martins, Carlo de Oliveira, et al.
Publicado: (2014)

Contractile properties of the right atrial myofilaments in patients with myxomatous mitral valve degeneration
por: Bening, Constanze, et al.
Publicado: (2014)

The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration
por: Tang, Qiyu, et al.
Publicado: (2022)

Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration
por: Tan, Karen, et al.
Publicado: (2019)

Effect of standard‐dose and high‐dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease
por: Kaplan, Joanna L., et al.
Publicado: (2022)

Myxomatous Mitral Valve with Prolapse and Flail Scallop
por: Fan, Jerry, et al.
Publicado: (2016)

Retrospective evaluation of notched and fragmented QRS complex in dogs with naturally occurring myxomatous mitral valve disease
por: Baisan, Radu Andrei, et al.
Publicado: (2021)

Infectious agents is a risk factor for myxomatous mitral valve degeneration: A case control study
por: Tiveron, Marcos Gradim, et al.
Publicado: (2017)

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020)

Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1
por: Tomsič, Katerina, et al.
Publicado: (2023)

Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)

Intestinal Complication With Myxomatous Mitral Valve Diseases in Chihuahuas
por: Araki, R., et al.
Publicado: (2021)

Amlodipine decreases mitral regurgitation volume in dogs over 7 days: A study of 24 dogs with myxomatous mitral valve degeneration
por: Park, Sool Yi, et al.
Publicado: (2022)

Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease
por: Galizzi, Alberto, et al.
Publicado: (2021)

Mitral valvuloplasty with left atrial appendage closure and pacemaker implantation in a dog with severe myxomatous mitral valve degeneration: a case report
por: Yoshida, Tomohiko, et al.
Publicado: (2022)

Telotristat ethyl reverses myxomatous changes in mice mitral valves
por: Wang, Xinmei, et al.
Publicado: (2022)

Pharmacokinetics of Pimobendan and Its Metabolite O-Desmethyl-Pimobendan Following Rectal Administration to Healthy Dogs
por: Her, Jiwoong, et al.
Publicado: (2020)

Antioxidant capacity of lipid- and water-soluble antioxidants in dogs with subclinical myxomatous mitral valve degeneration anaesthetised with propofol or sevoflurane
por: Tomsič, Katerina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ud3p4cpd7d4fmk6igeu36lssos